C&EN Webinars

C&ENjobs has tailored digital and print recruitment products to better assist institutions and organizations looking to advance their recruitment campaigns. We are the only career center that allows employers to reach 176,000 ACS members and 31 million scientific researchers via multiple touchpoints. Start...

C&EN's Weekly Newsletter keeps you up to date with what—and who—is making news in the world of chemistry: the most important research findings, the emerging trends you need to know to get ahead, plus the latest jobs in chemistry.

Subscribe now: https://connect.discoveracs.org/weeklynewsletter?pa...

Read our featured white papers and eBooks. Download below at any time.
https://cen.acs.org/collections/whitepapers.html

CAS Custom ServicesSM partners with clients to identify and solve their scientific information challenges, delivering unique solutions that help them accelerate informed decision-making, mitigate risk, and uncover insights that drive success.  

https://www.brainshark.com/cas/pharmaK...

Connect with the world’s scientific knowledge and find the answers you need to advance your research. Combine the comprehensive information and powerful tools found in CAS SciFinder® and complete your research tasks with confidence.

https://www.brainshark.com/cas/SFDPCommBrochure

Chemical & Engineering News announces 2023 list of 10 chemistry start-ups to watch

After several years of disruption and hard work, the pharmaceutical industry has dusted itself off and gotten back to business as usual. The number of drugs approved by the US Food and Drug Administration was certainly back up after 2022’s lean year, and drug companies with bulging coffers went on some high-profile spending sprees, snapping up biotechs to help their business development strategy as patent expirations loom.But what is business as usual? Our post-COVID-19 normality has changed our lives. In 2023, the pandemic-fueled pharma funding bubble also well and truly burst. Beyond the failure of Silicon Valley Bank and rising interest rates, investor sentiment seems to have cooled on biotechnology as a brand. Patients and industry executives are also watching to see how government-mandated price controls may begin affecting the pharma business.Both smaller biotechs and larger firms, such as Pfizer, Bayer, and GSK, ha...

With medicinal chemists’ innovative tools and techniques, it’s an exciting time to be building new drugs.

IN BRIEF
At one stage, small-molecule drugs seemed at risk of going out of fashion, as industry began to favor biotherapeutics. But over the past 10 years, small molecules have made it clear that they aren’t going away. New classes of molecules, such as proteolysis-targeting chimeras (PROTACs) and molecular glues, have people excited. So do technologies, such as machine learning and generative artificial intelligence, that are helping drive drug discovery. Today, drug hunters have more ambition to go after difficult targets and to use novel chemistry. And that makes it an exciting time for chemists.